ETIB opens clinical trial for patients with HPV-16+ cancers
These CT scan images show a patient with metastatic cervical cancer who was treated with a single infusion of anti-tumor T cells and experienced complete regression. Four years later, the patient remains cancer free.
Dr. Christian Hinrichs, Lasker Clinical Research Scholar in the Experimental Transplantation and Immunology Branch, is leading a study of a new therapy for cancers caused by human papillomavirus (HPV), which include cervical, throat, anal, and genital cancers. HPV-related cancer cells carry a protein called E7. Researchers will remove some white blood cells and insert genes into those cells that will make them attack cancer cells that have the E7 protein. Patients may also receive a drug to boost the effect of the E7 TCR cells. The goal of this study is to find a safe dose of E7 TCR and to see whether these cells can effectively fight cancer cells. Adults 18 or older with HPV-related cancers may contact Erin Ferraro, RN, at 301-594-0687 to discuss eligibility. View more information about this trial.
Summary Posted: Thu, 09/01/2016